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Abstract
Background: The majority of undiagnosed diseases manifest with objective findings that warrant further
investigation. The Undiagnosed Diseases Network (UDN) receives applications from patients whose symptoms and
signs have been intractable to diagnosis; however, many UDN applicants are affected primarily by subjective
symptoms such as pain and fatigue. We sought to characterize presenting symptoms, referral sources, and
demographic factors of applicants to the UDN to identify factors that may determine application outcome and
potentially differentiate between those with undiagnosed diseases (with more objective findings) and those who
are less likely to have an undiagnosed disease (more subjective symptoms).
Methods: We used a systematic retrospective review of 151 consecutive Not Accepted and 50 randomly selected
Accepted UDN applications. The primary outcome was whether an applicant was Accepted, or Not Accepted, and,
if accepted, whether or not a diagnosis was made. Objective and subjective symptoms and information on prior
specialty consultations were collected from provider referral letters. Demographic data and decision data on
network acceptance were gathered from the UDN online portal.
Results: Fewer objective findings and more subjective symptoms were found in the Not Accepted applications.
Not Accepted referrals also were from older individuals, reported a shorter period of illness, and were referred to
the UDN by their primary care physicians. All of these differences reached statistical significance in comparison with
Accepted applications. The frequency of subspecialty consults for diagnostic purposes prior to UDN application was
similar in both groups.
Conclusions: The preponderance of subjective and lack of objective findings in the Not Accepted applications
distinguish these from applicants that are accepted for evaluation and diagnostic efforts through the UDN. Not
Accepted applicants are referred primarily by their primary care providers after multiple specialist consultations fail
to yield answers. Distinguishing between patients with undiagnosed diseases with objective findings and those
with primarily subjective findings can delineate patients who would benefit from further diagnostic processes from
those who may have functional disorders and need alternative pathways for management of their symptoms.
Trial registration: clinicaltrials.gov NCT02450851, posted May 21st 2015.
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Background
Undiagnosed diseases are defined as constellations of find-
ings that remain refractory to medical diagnostic ap-
proaches. Undiagnosed diseases affect approximately 30
million Americans and include (a) rare diseases that are
difficult to identify, (b) atypical presentations of known dis-
orders, and (c) yet to be described diseases [1]. Undiag-
nosed diseases typically manifest with objective findings,
which are clinically measurable on physical examination or
through medical testing and these provide tangible targets
for further diagnostic approaches (e.g. dysmorphic facies,
abnormal biochemical profiles, physical exam demonstrat-
ing weakness or abnormal gait). Approximately 80% of
rare and undiagnosed disorders have a genetic basis [1].
The National Institutes of Health established a
multi-site network of clinical sites and core laboratories,
the Undiagnosed Diseases Network (UDN), in 2013 [2, 3]
(https://undiagnosed.hms.harvard.edu) to facilitate the
diagnosis/research of undiagnosed and rare diseases.
Network-wide, the UDN receives approximately 70 appli-
cations each month from adults and parents of children
with unexplained illnesses. Application to the UDN is
open to all individuals who complete the application with
a referral letter from a healthcare provider. The clinical
sites make decisions after a comprehensive review of an
applicant’s medical records. The network accepts about
half (51.8%) for further evaluation. UDN applicants have a
wide range of objective and subjective (non-objective)
symptoms; however we noticed that many applicants pre-
sented primarily or exclusively with subjective findings.
Subjective findings are non-objective, patient-reported
symptoms that are not verifiable by physical exam or
medical tests [4–6] (e.g. pain, fatigue, weakness that is
not substantiated by physical exam). Patients with sub-
jective findings may fall under the diagnostic terms of
functional disorder, central sensitivity syndrome, subject-
ive health complaints or even carry the DSM5 diagnosis
of somatic symptom disorder. It is difficult to estimate
the number of patients affected by these disorders,
although it represents a common conundrum in adult pri-
mary care medicine [7–9]. Many patients with primarily/
exclusively subjective findings may consider themselves to
have undiagnosed diseases and while a small number may
have underlying organic disease, the majority are not
believed to do so [6, 10].
Both patients with objective and subjective findings
accrue substantial healthcare costs and seek opinions
from multiple specialists, often undergoing extensive/in-
vasive diagnostic testing in their search for a diagnosis
[11–14]. Both groups also express chaos in their lives,
frustration with negative laboratory tests/procedures,
and seek validation of their symptoms [15]. This results
in significant personal psychosocial and financial distress
and a societal economic impact in both entities [16–19].
However, the likely underlying causes for each group are
different: Subjective findings have a number of predis-
posing risk factors and environmental triggers [20, 21]
and genetic factors are expected to play at most a mod-
est role [22]. Conversely, approximately 80% of undiag-
nosed disorders with clear objective findings have a
genetic etiology [1, 17, 23]. Thus, the diagnostic and
management approaches for each group differ, with
strategies focused on symptom management for the sub-
jective group and further diagnostic pathways, including
genomic sequencing for undiagnosed diseases with
objective findings.
Utilizing the UDN applicant cohort, we characterize
symptoms, referral patterns, and demographic factors
among applicants that are and are not accepted for
evaluation in the UDN. We sought to provide informa-
tion to healthcare providers and patients regarding
applicants that are suitable for further diagnostic avenues
such as the UDN, but more importantly we hope to
contribute to a discussion on the need for diagnostic/man-
agement/research pathways for applicants who suffer
primarily/exclusively from subjective findings.
Methods
We retrospectively reviewed 201 UDN applications: 151
consecutive applications that were not accepted (Not
Accepted Applicants) and 50 randomly selected applica-
tions that were accepted (Accepted Applicants) across
the seven UDN clinical sites (Additional file 1: Table S1).
All applicants provided electronic informed consent as
approved by the National Human Genome Research In-
stitute Institutional Review Board under research proto-
col 15-HG-0130.
Data were provided by the UDN Coordinating Center
from the online portal wherein network-wide information
is stored. Applications were included if the application
decision was issued between 3/1/2016 and 1/3/2017. We
excluded applications that were still under review by the
clinical sites and those that lacked a referral letter from a
healthcare provider. For all applications, we recorded
application outcome, applicant demographics, and appli-
cation metrics (e.g. referring healthcare provider data).
From study referral letters we recorded the number and
type of specialty consultations (if any) that were specific-
ally mentioned and medical information described by
healthcare providers. For Not Accepted Applicants only,
we recorded reasons for non-acceptance and recommen-
dations from the clinical site to the applicant/referring
healthcare provider (Additional file 1: Table S2).
On an initial review of 30 Not Accepted Applications,
we identified subjective symptoms that were commonly
mentioned in referral letters (Additional file 1: Table S3).
These were modified through consensus discussions by
three authors (NMW, LDMP, VS) and then extracted
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from all the letters. Objective findings varied greatly and
were tallied according to their presence in pertinent
organ systems (Additional file 1: Table S4). Findings
were considered to be objective if the healthcare pro-
vider mentioned an abnormal test or examination find-
ing by name. For example, muscle weakness counted as
an objective finding only if the provider documented
that the weakness was present on physical exam. If spe-
cific diagnoses, (e.g. fibromyalgia) were mentioned, these
were recorded separately.
Referring healthcare providers included physicians and
advance practice providers (e.g. physician assistants and
nurse practitioners) who wrote the UDN referral letter.
Physicians were classified as primary care physicians or
specific specialty when they identified themselves as
such, provided letterhead that included this information,
or were found via web search to practice family medi-
cine or general internal medicine. Advance practice pro-
viders were included in the category “Other” irrespective
of their specialty.
Statistical analyses were performed using SPSS 24.0. We
used descriptive analyses, student’s T-test, Fisher’s exact
test (FET), ANOVA, and chi-square analyses to analyze
factors that affected application outcome. Post-hoc ana-
lyses were performed when indicated to infer the signifi-
cance and direction of individual variables. Binary logistic
regression identified associations between the dependent




All UDN clinical sites were represented for the Not
Accepted and Accepted applications (Additional file 1:
Table S1). There were no significant differences between
the Accepted and Not Accepted applicants for gender,
race or ethnicity. The Accepted cohort was significantly
younger at the time of application and had earlier onset
of illness. The duration of illness in both groups was
similar but the proportion of an applicant’s life being ill
was significantly higher for the Accepted applicants. The
Not Accepted applications required a significantly longer
amount of time for application and medical record
review (Table 1).
Healthcare provider referral patterns
The most common source of referrals to the UDN were
primary care physicians (PCP) (88/201, 43.7%). PCP re-
ferrals accounted for significantly more applications that
were ultimately not accepted [55.6% of Not Accepted
applicants, 8.0% of Accepted Applicants, FET p < 0.001
(Table 2, Fig. 1a)]. Accepted Applicants were referred
most often by geneticists or neurologists (66%, Table 2).
We found no significant group differences in the number
Table 1 Demographic data of Not Accepted applicants compared to Accepted applicants
Feature Not Accepted (n = 151) Accepted (n = 50) Statistics
Age at Application (years, mean ± SD) 39.02 ± 19.11 21.03 ± 18.83 t = 5.78**
Cohen’s d = 0.94
Age at Symptom Onset (years, mean ± SD) 30.31 ± 18.75 11.11 ± 18.0 t = 6.3**
Cohen’s d = 1.0
Duration of Illness (years, mean ± SD) 8.71 ± 9.91 9.92 ± 10.06 t = −0.75
Cohen’s d = − 0.12
Proportion of Lifetime Being Ill (percentage) 28.31 ± 29.79 66.69 ± 37.08 t = −6.6**
Cohen’s d = −1.14
Length of Application Review (months, mean ± SD) 3.4 ± 1.73 2.78 ± 1.76 t = 2.17*
Cohen’s d = 0.35
Gender
Female 79 (52%) 26 (52%) FET = 1.0
Male 72 (48%) 24 (48%)
Race
White 128 (84.7%) 42 (84%) χ2 = 0.10
African-American 7 (4.6%) 2 (4%)
Other 16 (10.7%) 6 (12%)
Ethnicity
Hispanic 11 (7.3%) 5 (10%) χ2 = 0.38
Non-Hispanic 124 (82.1%) 40 (80%)
Not reported 16 (10.6%) 5 (10%)
SD Standard deviation, FET Fisher’s exact test
All t-tests were two-tailed *p < 0.05 **p < 0.001
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of specialist consultations noted by study referral letters
(Accepted: 2.62 ± 2.66, Not Accepted: 3.12 ± 2.67, t = − 1.14,
p = 0.252, Cohen’s d effect size = 0.18).
Subjective symptoms and objective findings
The mean number of subjective symptoms was higher in
the Not Accepted applicants (4.1 ± 3.37) relative to the
Accepted (1.7 ± 2.10, t = 4.7, p < 0.001, Cohen’s d effect size
= 0.85). This remains true for subjective symptoms when
Accepted applicants are stratified according to whether
they did (N = 16) or did not (N = 34) receive a diagnosis in
the UDN (Not Accepted: mean 4.1 ± 3.37, Accepted-Not
Diagnosed mean 2.06 ± 2.33, Accepted-Diagnosed mean
0.94 ± 1.39 (ANOVA F = 11.9, p < 0.001)). The four most
common subjective symptoms (pain, fatigue, headache and
memory problems (Additional file 1: Table S3)) were
present significantly less frequently in applicants in the
Accepted cohort (χ2 = 15.43, p < 0.01) (Fig. 1b). The major-
ity (114/151, 75.5%) of the Not Accepted applicants had at
least one objective clinical finding but the mean number of
objective findings in the Not Accepted group (1.67 ± 1.6)
was significantly lower than in the Accepted group
(3.12 ± 1.53, t = − 5.4, p < 0.001, Cohen’s d = − 0.92).
This finding remained true when Accepted applicants
are again stratified by diagnosis (Not Accepted: mean
1.67 ± 1.64, Accepted-Not Diagnosed mean 3.21 ± 1.72,
Accepted-Diagnosed mean 2.94 ± 1.24 (ANOVA F = 15.0,
p < 0.001)). In the entire cohort of 201 applicants, there
were significantly more subjective symptoms in applicants
referred by a primary care physician (n = 88, 5.05 ± 3.50)
than other healthcare providers (n = 113, 2.20 ± 2.50,
t = 6.2, p < 0.001, Cohen’s d = 0.93) (Fig. 1c) and sig-
nificantly fewer objective findings in those referred by
a primary care physician (1.48 ± 1.61) than other
healthcare providers (2.46 ± 1.71, t = − 4.15, p < 0.001,
Cohen’s d = 0.6) (Fig. 1c).
Prior diagnoses
Specific diagnoses were mentioned in some Not Accepted
referral letters and the top four: Fibromyalgia, Chronic
Fatigue Syndrome, Mitochondrial disorder and Lyme
disease were collectively reported in 28/151 (18.5%) Not
Accepted applications, compared to 6/50 Accepted appli-
cations (12%) (FET p > 0.05). However, the individual diag-
nosis of fibromyalgia was reported significantly more
often in the Not Accepted applications (16/151, 10.6%)
relative to the Accepted (1/50, 2%, FET p = < 0.05). For
the other three diagnoses, there were no significant group
differences (FET p= > 0.05), with a frequency of 0–9% in
both groups (Additional file 1: Figure S1).
Reasons for non-acceptance Not Accepted applicants
were given reasons for this decision, the most common
being that the UDN was unlikely to make a diagnosis,
likely reflective of the lack of objective findings in refer-
ral letters (77/151, 51.0%). Specific recommendations
were provided to 33.8% (51/151) of the Not Accepted
applicants, including recommendations to pursue spe-
cific diagnostic tests and seek subspecialty care.
Categorization of illness Neurology was the most com-
mon system category selected by both Accepted (24/50,
48%) and Not Accepted applicants (44/151, 29.1%, FET
p < 0.05), followed by Allergy-Immunology (8% in
Accepted and 10.5% in Not Accepted) and Musculo-
skeletal (12% in Accepted and 7.9% in Not Accepted).
No applicant in either group chose Psychiatry as their
disease category; objective psychiatric findings were
documented in three Not Accepted healthcare provider
letters (Additional file 1: Table S4).
Outcome associations On binary logistic regression
with the referring healthcare provider specialty, age at
application and age at symptom onset as independent
variables and application outcome as the dependent vari-
able, a primary care referral was significantly associated
with non-acceptance. Age at application and age at
symptom onset were not significantly associated with
acceptance status. Similarly, binary logistic regression
with the presenting findings showed that higher number
Table 2 Applicant referral sources for all applicants and Reasons for Non-Acceptance for the Not Accepted applications
Healthcare Provider Not Accepted Accepted Statistics
Primary Care Physicians compared to other Specialty Healthcare Providers
Primary Care Physician 84 (55.6%)a 4 (8.00%)a χ2 = 55.48, p < 0.001
Specialist: Neurologist 18 (11.9%) 14 (28.0%)a
Specialist: Geneticist 8 (5.3%)a 19 (38.0%)a
Other (e.g. Allergy Immunologist, Rheumatologist) 41 (27.2%) 13 (26%)
Primary Care Physicians compared to all Other Healthcare Providers
Primary Care Physicians 84 (55.6%) 4 (8%) FET p < 0.001
Others 67 (44.3%) 46 (92%)
aSignificant adjusted residuals exceeding +/− 2 on post-hoc testing
FET Fisher’s exact test
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of objective symptoms and fewer subjective symptoms were
significantly associated with being accepted (Table 3).
Discussion
Our findings indicate that many applicants that are not
accepted to the UDN suffer primarily from subjective
symptoms. Further, Not Accepted Applicants were more
often adults who had experienced illness for a shorter
proportion of their lives and had more non-neurological
presentations. Although objective and subjective symp-
toms were seen in both groups, higher numbers of
subjective symptoms were reported for Not Accepted
Applicants relative to Accepted subjects. This is true
regardless of whether an Accepted applicant was diag-
nosed by the UDN or not, indicating that a functional dis-
order was less likely in these remaining still-undiagnosed
Accepted applicants, distinguishing them from the Not
Accepted applicants. When objective findings were noted
in the Not Accepted applicants, these were often unre-
lated to the reasons for applying to the UDN (e.g. iron
deficiency anemia, abnormal thyroid profile) or were
non-specific (e.g. positive anti-nuclear antibody). Taken
together, we infer that Not Accepted subjects suffer pri-
marily from subjective symptoms that are unlikely to be
caused by or related to any objective findings. As such,
these applicants are not candidates for further diagnostic
Fig. 1 Referral sources and common symptoms in UDN applications . 1A: Not Accepted individuals were significantly more likely to be referred
by their primary care physicians than healthcare providers in all other disciplines combined (FET, p < 0.001). 1B: The four most often reported
symptoms in the Not Accepted group are reported significantly less frequently in the Accepted group (χ2 = 15.43, p < 0.01). 1C: Referral letters
authored by primary care physicians mentioned significantly more subjective symptoms (t = 6.2, p < 0.001) and fewer objective findings (t = − 4.15,
p < 0.001) than letters authored by other providers regardless of application outcome
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efforts such as those offered by the UDN. Interestingly,
the Not Accepted Applications took longer to review, per-
haps due to a higher volume of medical records that
needed to be reviewed to determine if there were features
(such as objective findings beyond subjective symptoms)
that would warrant acceptance, although we specifically
did not ascertain the reasons for review time.
We also found that primary care physicians referred
the largest proportion of applicants to the UDN, but that
their referrals had fewer objective findings and were less
likely to be accepted. We did not identify a clear reason
for this finding, but given that there is no difference in
the number of specialty consultations between Not
Accepted Applicants and Accepted Applicants, a lack of
access to specialists is unlikely. Instead, we presume this
indicates that patients with non-objective symptoms
continue to seek diagnostic efforts and additional refer-
rals through their PCPs after consultations with special-
ists do not provide a diagnosis [24].
In the context of the UDN, and perhaps more import-
antly in the setting of clinical practice, it is important to
make a distinction between undiagnosed patients with
and without objective findings. Undiagnosed patients with
clear objective findings are expected to have a genetic
basis in most instances; therefore these diseases can
reasonably be expected to be solved (eventually) with
additional tests, procedures, and genomic investigations.
The UDN is one of several avenues available to pursue a
unifying diagnosis. For patients with primarily/exclusively
subjective symptoms, additional clinical or genomic inves-
tigations are likely to provide a concrete diagnosis in only
a small minority (< 5%) of cases [10, 25]. There is evidence
that risk factors may play a part, such as stress, underlying
mood disorders and viral infections, and there are several
diagnostic terms, including “functional disorder,” “central
sensitivity syndrome,” or “somatic symptom disorder” that
may fit these individuals [20, 21]. Whether these diagnoses
have been discussed with these UDN applicants is not
ascertainable from the data available, but it is certain that
these applicants attribute their symptoms to a physical
illness that requires additional diagnostic efforts.
Despite the dichotomy between undiagnosed patients
with and without objective symptoms, the societal and
personal impact is remarkably similar. Both groups incur
high medical costs and the affected individuals are often
significantly disabled. In our recent analysis of UDN nar-
ratives, all applicants expressed similar levels of chaos in
their lives and frustration with negative laboratory tests/
procedures and many stated that the UDN represented
their last hopes for a diagnosis [15].
Although the UDN provides recommendations for
applicants and their physicians whenever appropriate, in
many cases the onus of continuing medical investigation
and treatment falls to primary care physicians, who them-
selves have limited resources, especially limited time, and
few research avenues available to them in their efforts to
diagnose/treat patients with subjective findings. There are
some research studies that may be an option (https://
mecfs.ctss.nih.gov; https://painconsortium.nih.gov), but
there are only a few specific clinical programs (http://
www.chop.edu/centers-programs/center-amplified-muscu
loskeletal-pain-syndrome; http://www.amazingkids.org/
Medical-Services/pain-rehabilitation) to address non-ob-
jective symptoms, and they are treat primarily children.
The diagnostic terms “functional disorder,” “central sensi-
tivity syndrome,” or “somatic symptom disorder” were
almost never identified in referral letters, indicating that
PCPs may not be discussing these. Clearly more avenues
for management of subjective symptoms are needed
beyond the care that PCPs may be able to provide these
patients.
This study has some limitations that future research ef-
forts may address. We were unable to ascertain a compre-
hensive list of subjective/objective findings directly from
medical records review. We may have under-ascertained
primary care provider referrals because all mid-level pro-
viders were classified as “other” regardless of specialty. We
were unable to speak with referring providers directly, and
future studies that consider these discussions may provide
additional insights into a physician’s motivations for refer-
ral. We were not able to follow applicants after a decision
was made and so do not know if any of the Not Accepted
applicants received a diagnosis. We also did not have
socioeconomic status data available and these may have
influenced the types of applications received.
Conclusions
In conclusion, making a distinction between undiag-
nosed diseases with and without objective findings
enable the affected individuals and their providers, who
very often are PCPs, to identify the correct path forward
for further management. Confusing subjective symptoms
Table 3 Logistic regression demonstrating relation between key
demographic and medical variables and Acceptance or Non-
Acceptance into the UDN
Criterion Odds ratio 95% Confidence
Interval
Demographics
Age at UDN Application 1.01 0.98–1.05
Age at onset of symptoms 1.03 0.99–1.07
Referring healthcare provider
(Primary care or Other)
8.86*** 2.84–26.5
Medical Findings
Subjective Symptoms 1.40*** 1.19–1.66
Objective Findings 0.62*** 0.5–0.76
*p < 0.05, **p < 0.01, ***p < 0.001
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for undiagnosed diseases can lead to significant loss of
time and resources to identify diagnoses, when further
management of the symptoms would be more optimal.
Given the prevalence of subjective findings in the general
population additional research is warranted in this area to
provide clinically appropriate diagnostic guidelines, estab-
lish evidence-based treatment options and facilitate honest
and effective communication about these illnesses with
the patients.
Additional file
Additional file 1: Figure S1. Referral sources and common symptoms
in UDN applications. 1A: Not Accepted individuals were significantly
more likely to be referred by their primary care physicians than
healthcare providers in all other disciplines combined (FET, p < 0.001). 1B:
The four most often reported symptoms in the Not Accepted group are
reported significantly less frequently in the Accepted group (χ2 = 15.43, p
< 0.01). 1C: Referral letters authored by primary care physicians
mentioned significantly more subjective symptoms (t = 6.2, p < 0.001) and
fewer objective findings (t = − 4.15, p < 0.001) than letters authored by other
providers regardless of application outcome. These materials contain 4
additional data tables and one supplementary figure. (DOCX 63 kb)
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